ATAna Teixeira

Ana Teixeira

*This is an algorithmically generated author record based on publicly available information.

Ana Teixeira has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The European Society of Pediatric Nephrology Board Examination—a certified benchmark of knowledge and clinical practice with global recognition

    by Ana Teixeira, Stella Stabouli, Rezan Topaloglu, Aysun Karabay Bayazit, Olivia Boyer, Dorota Drozdz, Rukshana Shroff, Martin Christian, Zainab Arslan, Justine Bacchetta, et al.

    Background: Subspecialty recognition and certification in Pediatric Nephrology remain heterogeneous across Europe and globally, resulting in variations in training standards and professional mobility. To address this gap, the European Society for Paediatric Nephrology (ESPN) launched the European Board Certification in 2020 as a pan-European and curriculum-based assessment of knowledge and clinical reasoning in Pediatric Nephrology. Methods: We performed a descriptive and analytical evaluation of candidates who applied for the ESPN Board Certification in Pediatric Nephrology between 2020 and 2025. Candidate characteristics, examination performance, and factors associated with success were analyzed. The exam consisted of 100 case-based multiple-choice questions developed according to a predefined blueprint. Multivariable logistic regression was used to identify factors independently associated with passing. Additionally, a cross-sectional survey assessed candidates’ perceptions of the examination and its professional impact. Results: A total of 349 pediatric nephrologists from 52 countries and four continents completed the examination. Median age was 38.2 years (IQR 34.7–43.5), and 59.9% were female. The overall pass rate was 54.7%, with significant variation by continent ( p = 0.014). Attendance at the International Pediatric Nephrology Association (IPNA)-ESPN Junior Master Class was associated with higher odds of success (OR 3.76, 95% CI 1.65–5.87, p < 0.001), whereas increasing age was associated with lower odds of success (OR 0.66 per additional year, 95% CI 0.55–0.78, p = 0.002). Among 74 survey respondents, perceptions regarding the examination were highly positive: 93.2% considered the content clinically relevant, 89.2% reported increased self-confidence, and 75.6% perceived a positive professional impact. Conclusions: Since its launch, the ESPN Board Examination has emerged as an internationally acknowledged benchmark of key knowledge and clinical reasoning in Pediatric Nephrology. Structured preparatory education enhances examination success, and certification is widely perceived as professionally meaningful. The examination plays a vital role in standardizing subspecialty criteria and reinforcing the professional identity within Pediatric Nephrology.

  • Open Access

    Doença antimembrana basal glomerular em crianças: o Sars-Cov-2 pode ser um fator desencadeador?

    by André Costa Azevedo, Ricardo Domingos Grilo, Ana Patrícia Rodrigues, Ana Losa, Liane Correia-Costa, Ana Teixeira, Liliana Rocha, Paula Matos, Teresa Costa, Maria Sameiro Faria, et al.

    Um jovem de 17 anos, do sexo masculino, caucasiano, fumante (20 cigarros/dia), sem qualquer outro consumo de drogas ou álcool, previamente vacinado com duas doses da vacina contra o SARS-CoV-2 e com histórico clínico normal, apresentou-se ao pronto-socorro pediátrico com histórico de 11 dias de dispneia aos pequenos esforços, toracalgia e expectoração sanguinolenta nos últimos 4 dias. Na apresentação, o exame revelou palidez cutânea, desconforto respiratório, hipoxemia (saturação de 87% em ar ambiente) e crepitações na ausculta pulmonar. Os exames laboratoriais iniciais ( Tabela 1) foram positivos para leucocitose (14340/μL), neutrofilia (10700/μL), proteína C reativa elevada (148,4 mg/L) e função renal normal (creatinina sérica de 0,74 mg/dL/dL e ureia sérica de 24 mg/dL). Devido ao desconforto respiratório significativo, foi realizada uma angiotomografia computadorizada (Angio-TC) de tórax, que revelou múltiplas opacidades micronodulares, excluindo a possibilidade de embolia pulmonar. O teste de reação em cadeia da polimerase (PCR) para SARS-CoV-2 também foi realizado e obteve-se um resultado positivo. O paciente foi internado com oxigênio suplementar, mas o desconforto respiratório piorou a ponto de exigir suporte ventilatório. Ele foi transferido para a unidade de terapia intensiva pediátrica (UTIP) para cuidados e manejo adicionais. Durante sua permanência na UTIP, a angio-TC foi repetida, demonstrando uma consolidação com atelectasia centrada nos segmentos apical e posterior dos pulmões (demonstrada na Figura 1). O parênquima remanescente era arejado e preenchido por múltiplas opacidades difusas, centrolobulares e micronodulares que poupavam apenas a superfície pleural e as fissuras, um padrão que era sugestivo de pneumonite de hipersensibilidade subaguda. O paciente começou a receber antibióticos intravenosos (a piperacilina-tazobactam foi trocada por imipenem e vancomicina devido à piora clínica e a um aumento nos marcadores inflamatórios). Foram realizados estudos imunológicos que se mostraram negativos para os seguintes anticorpos: antinuclear (ANA), anticitoplasmático de neutrófilos (ANCA), anticardiolipina, anti-antígeno nuclear extraível (ENA) e fator reumatoide. As hemoculturas e as culturas bacteriológicas e micológicas de secreções respiratórias foram negativas. O Ensaio de Liberação de Interferon Gama (IGRA) também foi negativo. O quadro clínico do paciente piorou e mostrou-se refratário à ventilação mecânica. Ele foi colocado em oxigenação por membrana extracorpórea (ECMO) e começou a receber terapia com altas doses de esteroides. A broncoscopia e o lavado broncoalveolar mostraram neutrofilia e hemorragia alveolar leve, e os exames de cultura foram negativos. Clinicamente, a condição do paciente melhorou, as doses de esteroides foram progressivamente reduzidas e a ECMO foi interrompida. Após a decanulação da ECMO, foi realizado doppler cervical que revelou a presença de um trombo preenchendo 20% do lúmen da veia jugular interna direita. Os achados Doppler das veias dos membros inferiores foram normais. A anticoagulação foi iniciada com apixabana. Durante essa internação, amostras seriadas de sangue mostraram uma normalização lenta dos níveis dos marcadores inflamatórios. Não houve mais episódios de hemoptise e a função renal permaneceu normal, com nível máximo de creatinina sérica de 0,63 mg/dL e 0,51 mg/dL na alta para uma unidade de reabilitação ( Tabela 1) devido à miopatia por desuso grave. Durante sua permanência na unidade de reabilitação, o paciente permaneceu hemodinamicamente estável com débito urinário normal até dois meses após a admissão, quando apresentou febre e hematúria macroscópica. O paciente foi imediatamente transferido para a Unidade de Nefrologia Pediátrica.

  • Open Access

    Anti-glomerular basement membrane disease in children: can Sars-Cov-2 be a trigger?

    by André Costa Azevedo, Ricardo Domingos Grilo, Ana Patrícia Rodrigues, Ana Losa, Liane Correia-Costa, Ana Teixeira, Liliana Rocha, Paula Matos, Teresa Costa, Maria Sameiro Faria, et al.

    A 17-year-old Caucasian male, smoker (20 cigarettes/day), without no other drug or alcohol consumption, previously vaccinated with two doses of SARS-CoV-2 vaccine and with an unremarkable medical history, presented to the pediatric emergency department with an 11-day history of dyspnea on mild exertion, thoracalgia, and bloody sputum for the previous 4 days. At presentation, examination revealed cutaneous pallor, respiratory distress, hypoxemia (saturation of 87% on room air), and crackles on pulmonary auscultation. Initial laboratory tests ( Table 1) were positive for leukocytosis (14340/μL), neutrophilia (10700/μL), elevated C-reactive protein (148.4 mg/L), and normal kidney function (serum creatinine of 0.74 mg/dL/dL and serum urea of 24 mg/dL). Due to significant respiratory distress, computed tomography angiography (Angio-CT) of the thorax was performed, revealing multiple micronodular opacities, and pulmonary embolism was excluded. Polymerase chain reaction (PCR) testing for SARS-CoV-2 was also performed, and a positive result was obtained. The patient was admitted on supplemental oxygen, but respiratory distress worsened to the point of requiring ventilatory support. He was transferred to the pediatric intensive care unit (PICU) for further care and management. During his stay in the PICU, angio-CT was repeated, demonstrating a consolidation with atelectasis centered in the apical and posterior segments of the lungs (shown in Figure 1). The remaining parenchyma was airy and filled with multiple diffuse, centrilobular, micronodular opacities that only spared the pleural surface and fissures, a pattern that suggested subacute hypersensitivity pneumonitis. He was started on intravenous antibiotics (piperacillin-tazobactam was switched to imipenem and vancomycin due to clinical worsening and an increase in inflammatory markers). Immunological studies were performed and proved negative for the following antibodies: anti-nuclear (ANA), anti-neutrophil cytoplasmatic (ANCA), anti-cardiolipin, anti-extractable nuclear antigen (ENA), and rheumatoid factor. Blood cultures and bacteriological and mycological cultures of respiratory secretions were negative. Interferon Gamma Release Assay (IGRA) was also negative. The patient’s clinical condition deteriorated, and showed to be refractory to mechanical ventilation. He was placed on extracorporeal membrane oxygenation (ECMO) and started on high-dose steroid therapy. Bronchoscopy and bronchoalveolar lavage showed neutrophilia and mild alveolar hemorrhage, and culture exams were negative. Clinically, the patient’s condition improved, steroid doses were progressively decreased, and ECMO was stopped. After ECMO decannulation, cervical doppler was performed, revealing a thrombus filling 20% of the lumen of the right internal jugular vein. Doppler findings of the lower limb veins were normal. Anticoagulation was initiated with apixaban. During this hospitalization, serial blood samples showed slow normalization of the inflammatory markers’ levels. There were no further episodes of hemoptysis and kidney function remained normal, with a maximum serum creatinine level of 0.63 mg/dL, and 0.51 mg/dL at discharge to a rehabilitation unit ( Table 1) due to severe disuse myopathy. During his stay in the rehabilitation unit, the patient remained hemodynamically stable with normal urinary output until 2 months after admission, when he developed fever and gross hematuria. The patient was immediately transferred to the Pediatric Nephrology Unit.


  • Open Access

    Rituximab therapy for childhood onset idiopathic nephrotic syndrome: experience of a Portuguese tertiary center

    by Rita Gomes, Sara Mosca, Mariana Bastos-Gomes, Liane Correia-Costa, Liliana Rocha, Ana Teixeira, Teresa Costa, Maria Sameiro-Faria, Paula Matos, Conceição Mota

    Introduction: Rituximab (RTX) is a therapeutic option in pediatric difficult-to-treat idiopathic nephrotic syndrome (NS). We aimed to assess the efficacy and safety of RTX use in these patients. Method: A retrospective study of all patients with idiopathic NS treated with RTX was conducted in a pediatric nephrology division of a tertiary hospital. Demographic, anthropometric, clinical and analytical data were collected prior to treatment and at 6, 12, and 24 months. Results: Sixteen patients were included (11 males), with a median (25th–75th percentile, P25–P75) age at diagnosis of 2 (2.0–2.8) years. Fifteen were steroid-sensitive and 1 was steroid-resistant and sensitive to cyclosporine. The median age at administration of RTX was 10 (6.3–14.0) years. Throughout a median follow-up time of 2.5 (1.0–3.0) years, 6 (37.5%) patients achieved partial remission and 7 (43.8%) had no relapses and were not taking any immunosuppressants at the 24-month follow-up visit. Regarding complications, 1 patient presented persistent hypogammaglobulinemia. Compared with the 12-month period before RTX, there was a decrease in the median number of relapses at 6 and 12 months [3 (3.0–4.0) vs 0 (0–0.8) and 0.50 (0–1.0), respectively; p = 0.001] and in the daily steroids dose (mg/kg/day) at 6, 12, and 24 months [0.29 (0.15–0.67)vs [0.10 (0.07–0.13); p = 0.001], [0.12 (0.05–0.22); p = 0.005] and [0.07(0.04–0.18); p = 0.021]], respectively. There was also a reduction in the median BMI z score at 24 months [2.11 (0.45–3.70) vs. 2.93 (2.01–3.98); p = 0.049]. Conclusion: Our results confirm the efficacy and safety of RTX use in pediatric idiopathic NS and highlight its’ potential cardiometabolic benefits.


  • Open Access

    Terapia com Rituximabe para síndrome nefrótica idiopática de início na infância: experiência de um centro terciário português

    by Rita Gomes, Sara Mosca, Mariana Bastos-Gomes, Liane Correia-Costa, Liliana Rocha, Ana Teixeira, Teresa Costa, Maria Sameiro-Faria, Paula Matos, Conceição Mota

    Resumo Introdução: Rituximabe (RTX) é uma opção terapêutica na síndrome nefrótica (SN) idiopática pediátrica de difícil tratamento. Visamos avaliar eficácia e segurança do uso de RTX nestes pacientes. Método: Realizou-se estudo retrospectivo de todos os pacientes com SN idiopática tratados com RTX, em uma unidade de nefrologia pediátrica de um hospital terciário. Dados demográficos, antropométricos, clínicos e analíticos foram coletados antes do tratamento e aos 6, 12 e 24 meses. Resultados: Incluímos 16 pacientes (11 do sexo masculino), com idade mediana (percentil 25–75, P25–P75) de 2 (2,0–2,8) anos ao diagnóstico. Quinze eram sensíveis a esteroides, e 1 resistente a esteroides e sensível à ciclosporina.A idade mediana na administração do RTX foi 10 (6,3–14,0) anos. Durante um tempo mediano de acompanhamento de 2,5(1,0–3,0) anos, 6 (37,5%) pacientes alcançaram remissão parcial e 7 (43,8%) não tiveram recidivas e não estavam tomando imunossupressor no acompanhamento aos 24 meses. Quanto às complicações,1 paciente apresentou hipogamaglobulinemia persistente. Comparado ao período de12 meses anterior ao RTX, houve diminuição no número mediano de recidivas em 6 e 12 meses [3 (3,0–4,0) vs 0 (0–0,8) e 0,50 (0–1,0), respectivamente; p = 0,001] e na dose diária de esteroides (mg/kg/dia) aos 6, 12 e 24 meses [0,29 (0,15–0,67) >vs [0,10 (0,07–0,13); p = 0,001], [0,12 (0,05–0,22); p = 0,005] e [0,07 (0,04–0,18); p = 0,021], respectivamente. Houve também redução na mediana do escore z do IMC aos 24 meses [2,11 (0,45–3,70) vs 2,93 (2,01–3,98);p = 0,049]. Conclusões: Nossos resultados confirmam a eficácia e segurança do uso de RTX em SN idiopática pediátrica, destacando seus potenciais benefícios cardiometabólicos.


  • IPNA–ESPN Junior Master Class—a decade of successful continuing education and training in pediatric nephrology

    by Ana Teixeira, Rezan Topaloglu, Pierre Cochat, Rosanna Coppo, Elena Levtchenko, Dieter Haffner, John D. Mahan, Jun Oh


  • Open Access

    Genetic atypical hemolytic uremic syndrome in children: a 20-year experience from a tertiary center

    by Cristiana Maximiano, Andreia Silva, Inês Duro, Tiago Branco, Liane Correia-Costa, Ana Teixeira, Liliana Rocha, Teresa Costa, Paula Matos, Maria Do Sameiro Faria, et al.

    Introduction: Atypical hemolytic uremic syndrome (aHUS) is a rare disorder characterizedby the triadof microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, which primarily affects preschool-aged children. This study's aim was to describe the clinical profile, management, and long-term outcome of the genetic aHUS patients admitted to a tertiary care pediatric nephrology center during 20 years. Methods: We performed a retrospective analysis of the clinical records of all aHUS patients younger than 18 years with identified genetic mutations. Data on clinical features, genetic study, therapeutic interventions, and longterm outcomes were reviewed. Results: Five cases of aHUS with an identified genetic mutation were included; all were inaugural cases with the youngest being 4 months old. Complement factor H gene mutation was identified in four patients. Therapeutic plasma exchange was performed for acute management in 4 patients, one of whom also needed acute renal replacement therapy (peritoneal dialysis). All patients went on complete remission, 2 had more than one relapse but only 1 of these progressed to chronic kidney disease during the followup period (median (25th-75th percentile), 136 (43.5-200.5) months). Conclusion: In children, the prognosis of renal function seems to be strongly dependent on the genetic background, thus being crucial to perform genetic study in all aHUS cases. In our cohort, 2 patients presented genetic mutations not previously described. Recent innovations on the genetic field leading to the identification of new mutations has lead to a better understanding of aHUS pathogenesis, but further studies, focusing on the genotype-phenotype correlation, with longer follow-p periods, are needed.